Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Intraperitoneal administration of Dianeal with 4.25% dextrose creates an osmotic gradient across the peritoneal membrane, promoting ultrafiltration and removal of uremic toxins and excess fluid.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal administration: 2 liters infused over 10-20 minutes, dwell time 4-6 hours, then drain over 15-20 minutes; 4 exchanges per 24 hours.
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Dextrose: approximately 1.5–2 hours (systemic half-life in renal impairment; peritoneal equilibration half-life for dextrose in dialysate is 1–2 hours, reflecting absorption).
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Peritoneal dialysis: Dextrose is metabolized systemically and eliminated primarily as CO2. Unchanged dextrose undergoes renal elimination only in anuric patients on dialysis, with minimal biliary/fecal excretion (<2%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution